Project Grant R01DK141016

Award Date 9/10/24
Completion Date 6/30/29
Dollars Obligated $1.6M
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Roxbury, MA 02118, USA
Similar Awards
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $499,890 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Pavaj Vascular Corporation to develop a novel therapy to prevent arteriovenous fistula (AVF) venous stenosis, a common complication in end-stage kidney disease patients requiring hemodialysis. The funding will support two main goals: 1) evaluating the stability and biocompatibility of a nanoparticle-based...
This $152,453 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support the development and validation of a deep learning approach to automatically assess kidney vascular pathology and predict cardiovascular risk from digitized kidney biopsy images. The award will be used by the Boston Medical Center Corporation to: 1) develop and validate an...
This Project Grant award of $200,000.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research to investigate the role of oxidative stress and the transcription factor Nrf2 in modulating the phenotype of vascular smooth muscle cells (VSMCs) and improving arteriovenous fistula (AVF) maturation. The research, to be conducted at the University of North...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $704,672 to Flowpoint Medical Inc. to develop an implantable self-sealing needle guide system to improve vascular access and safety for hemodialysis patients. The award will fund the refinement of the device's manufacturability and operational parameters, as well as a large animal...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $133,500 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Boston Medical Center Corporation (BMC) with a start date of September 1, 2024 and end date of August 31, 2026. The grant will fund research on the relationship between APOL1 genotypes and biomarkers of immune activation and tubular injury in the context of chronic kidney disease (CKD) in sub-Saharan...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is focused on developing novel bioengineered regenerative medicine solutions based on vasculogenic regenerative medicine technology. The $543,826 award, granted on December 10, 2024, aims to investigate the mechanisms underlying in vivo vasculogenic reprogramming, specifically examining...
This $518,661 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to advance the design of hemodialysis cartridges beyond the focus on urea removal. The project will test a novel parallel-plate dialyzer design that controls shear forces to potentially reduce platelet activation and clotting risks for the 548,000 Americans who rely on dialysis. The award to Vanderbilt...
This $675,480 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to develop a novel therapeutic compound for treating chronic kidney disease (CKD). The awardee, Fibrotherapeutics Inc., is conducting preclinical studies to evaluate the efficacy, safety, and therapeutic index of a modified, water-soluble, orally-active peptide derived...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $436,277 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Delaware. The grant titled "NEPHROGENESIS ON A CHIP: AN SIMPLE MODULAR PLATFORM TO SPATIALLY PATTERN EXTRACELLULAR MATRIX, STROMAL CELLS, AND SOLUBLE FACTORS" aims to develop an easy-to-use 3D in vitro model of the developing nephron that allows spatial patterning...
This $400,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to understand the earliest events in podocyte injury in collagen IV nephropathies. The goal is to investigate how processing of mutant collagen IV proteins injures podocytes at early stages, leading to chronic kidney disease and renal failure. The research uses...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $1,583,229 Project Grant to Boston Medical Center Corporation to evaluate the use of intravascular ultrasound (IVUS) imaging for diagnosing and managing arteriovenous (AV) access dysfunction in end-stage kidney disease patients on hemodialysis. The 5-year grant project will compare the accuracy of IVUS versus standard angiography, and explore how IVUS-based stenosis, morphological, and hemodynamic parameters can guide AV access interventions and improve clinical outcomes. The University of Pennsylvania is a sub-awardee providing research support services for the project.

Generated 8/5/25, 2:47 AM